BDCA-2 mFc Chimera, Human
BDCA-2 MFc Chimera, Human

Immobilized BDCA-2 mFc Chimera, Human, mFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-BDCA-2 Antibody, hFc Tag with the EC50 of 5.7 ng/ml determined by ELISA.

BDCA-2 MFc Chimera, Human

BDCA-2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

BDCA-2 mFc Chimera, Human

BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
Z05076
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
mFc (IgG2a) BDCA-2 (Phe46-Ile213)
Accession # Q8WTT0-1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized BDCA-2 mFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti­BDCA­2 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 46.39 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl, 200mM L-arginine (pH 8.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • BDCA-2 MFc Chimera, Human
    • BDCA-2 MFc Chimera, Human

    Immobilized BDCA-2 mFc Chimera, Human, mFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-BDCA-2 Antibody, hFc Tag with the EC50 of 5.7 ng/ml determined by ELISA.

  • BDCA-2 MFc Chimera, Human
    • BDCA-2 MFc Chimera, Human

    BDCA-2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
Synonyms BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.